Growth over the past 12 months: Prescription drugs grew most rapidly among the major categories (13.0%). Physician and clinical services grew the slowest among major categories, at 2.9%. For the preceding 12-month period ending December 2013, prescription drugs showed the highest growth among the major categories, at 5.7%, whereas dental spending rose the least, by 1.0% (Exhibits 4 and 6).





Exhibit 4. Health Spending Year-Over-Year Growth for Selected Categories





## Average Annual Out-of-Pocket Costs for Specialty Drugs by Metal Level

Condition	Medication	Monthly Prescription Cost Without Insurance <sup>6</sup>	Bronze Annual Out- of-Pocket Cost	Silver Annual Out- of-Pocket Cost	Gold Annual Out-of- Pocket Cost	Platinum Annual Out- of-Pocket Cost
Inflammation	Humira	\$2,942.35	\$6,381.38	\$5,415.60	\$3,823.82	\$1,416.67
Multiple Sclerosis	Copaxone	\$5,508.86	\$6,385.71	\$5,491.59	\$3,920.58	\$1,416.67
Cancer	Gleevec	\$9,119.95	\$6,385.71	\$5,569.27	\$4,004.15	\$1,416.67
HIV	Atripla	\$2,186.49	\$6,373.16	\$5,373.46	\$3,763.25	\$1,406.42
Growth deficiency	Norditropin	\$5,096.07	\$6,385.71	\$5,482.43	\$3,911.03	\$1,416.67

Source: HealthPocket: Infostate, 8-26-2014, <u>http://www.healthpocket.com/healthcare-research/infostat/2015-obamacare-specialty-drug-costs#.VQOw1Y7F-n\_</u> accessed on March 13, 2015.

Source: Altarum monthly national health spending estimates



## High Prescription Drug Prices: It Must Be the R&D Right?



